Principles of treating and monitoring infections in immunosuppressed patients

Overview

Managing infection in patients on immunosuppressive rheumatological treatment requires balancing the increased infection risk/severity from the underlying immunosuppression against the ongoing need to control the underlying inflammatory disease - decisions are individualised, not governed by a single fixed rule
Infection is a leading cause of morbidity/mortality in patients on significant immunosuppression for rheumatic disease, and the risk compounds with combination immunosuppression, higher glucocorticoid doses, and specific agent-related risks (e.g. TB reactivation with anti-TNF)

Immunosuppression blunts the normal inflammatory/febrile response to infection, meaning infected patients on significant immunosuppression can present with minimal fever or localising signs despite serious infection - a low threshold for investigation is needed given this blunted presentation

Active infection generally requires holding or reducing immunosuppression (particularly biologics and high-dose conventional agents) while treating the infection, with the degree of held immunosuppression matched to infection severity and the risk of a disease flare from stopping treatment
Pre-treatment screening (latent TB, hepatitis B, varicella immunity - see pre-treatment screening for biological agents) reduces the risk of specific serious infections before starting significant immunosuppression, rather than only responding after infection occurs

Restart/resume immunosuppression once the infection is adequately treated, individualised by infection severity and disease flare risk - there is no single universal "safe" interval, and the decision should be made collaboratively considering both infection resolution and disease control needs
Vaccination status should be optimised proactively (see immunisation in the immunocompromised) before or during treatment, given the reduced vaccine response and live vaccine restrictions once significant immunosuppression has begun

Latent TB reactivation (anti-TNF specific risk), hepatitis B reactivation, opportunistic infection with combination immunosuppression, PJP prophylaxis considerations with high-dose/prolonged corticosteroids or certain combination regimens

A blunted or atypical infection presentation in a significantly immunosuppressed rheumatic disease patient is a recognised, important trap - "not looking that unwell" does not reliably exclude serious infection in this population, and investigation thresholds should be lower than in an immunocompetent patient with similar symptoms

5 more sections, plus exam facts

Premium unlocks every note across every specialty, and the full exam fact library behind it.